NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma Inc (NASDAQ:ALBO) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.18. The biopharmaceutical company earned $1.39 million during the quarter, compared to the consensus estimate of $1.38 million. Albireo Pharma had a negative net margin of 1,881.86% and a negative return on equity of 62.69%. View Albireo Pharma's Earnings History.

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

4 brokers have issued 1-year target prices for Albireo Pharma's shares. Their forecasts range from $39.00 to $69.00. On average, they expect Albireo Pharma's share price to reach $56.67 in the next twelve months. This suggests a possible upside of 129.0% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

News coverage about ALBO stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Albireo Pharma earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Albireo Pharma.

Albireo Pharma saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 688,900 shares, a decrease of 13.0% from the January 15th total of 791,600 shares. Based on an average daily volume of 77,500 shares, the short-interest ratio is presently 8.9 days. Approximately 6.8% of the company's stock are short sold. View Albireo Pharma's Current Options Chain.

Some companies that are related to Albireo Pharma include Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), Dermira (DERM), ImmunoGen (IMGN), Odonate Therapeutics (ODT) and Applied Therapeutics (APLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Martin Midstream Partners (MMLP), Cornerstone Total Return Fund (CRF), Palatin Technologies (PTN), Exelixis (EXEL), Viking Therapeutics (VKTX) and SandRidge Permian Trust (PER).

Albireo Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (6.83%), Point72 Asset Management L.P. (1.67%), State Street Corp (1.53%), Chicago Capital LLC (1.38%), Victory Capital Management Inc. (1.20%) and Victory Capital Management Inc. (1.20%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Heartland Advisors Inc., Victory Capital Management Inc., Victory Capital Management Inc., Goldman Sachs Group Inc., Blair William & Co. IL, State Street Corp and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

ALBO stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Point72 Asset Management L.P., Bank of Montreal Can, California Public Employees Retirement System, MAI Capital Management, Alpine Global Management LLC, Birchview Capital LP and M&T Bank Corp. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $24.74.

Albireo Pharma has a market capitalization of $313.95 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-46,110,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.View Additional Information About Albireo Pharma.

The official website for Albireo Pharma is http://www.albireopharma.com/.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]